Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
272.64
-4.69 (-1.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
October 13, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 Top Biotech Stocks Defying the Bear Market
October 11, 2022
Bear market, shmear market. These biotech stocks are soaring despite the market downturn.
Via
The Motley Fool
Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease
October 07, 2022
Via
Benzinga
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
October 06, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Alnylam Pharmaceuticals
October 03, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval
October 03, 2022
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
September 09, 2022
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Via
Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
October 03, 2022
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
October 03, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
September 30, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
September 22, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Alnylam Announces New Management Appointments
September 21, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
September 20, 2022
Via
Benzinga
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
September 20, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
September 19, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
September 15, 2022
Via
Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers
September 15, 2022
Via
Benzinga
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
September 15, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
September 13, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
September 13, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Why Alnylam Pharmaceuticals Shares Are Falling
September 12, 2022
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares are trading lower by 4.97% to $212.18 Monday morning after the company announced a proposed offering of $900 million convertible
Via
Benzinga
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
September 12, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
September 09, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
September 08, 2022
Via
Benzinga
Alnylam Shares Detailed Patisiran Data From Rare Disease Study
September 08, 2022
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Via
Benzinga
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
September 08, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.